Healthcare / Medical DevicesNasdaqGM
$12.80
+0.68 (+5.61%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 29% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-51.7M · quality 52.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
34/100
D
Piotroski
4/9
balance/quality
Valuation
30/100
-20.4% upside
5Y CAGR
+12.7%
100/100
Data QA
79/100
SEC 75%
Sin guardar todavía.
Market Cap
$570M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-25.5%
↓Gross Margin
55.4%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+724.3%
FCF CAGR
—
FCF margin
-56.1%
FCF / Net income
0.77x
Latest source
SEC-backed
Margin decomposition
Último año: revenue $100.3M · net income $-73.2M · FCF $-56.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025SEC | 2024SEC | 2023SEC | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $100.3M | $100.3M | $65.1M | $12.0M | $179000.00 |
| Net Income | $-73.2M | $-73.2M | $-54.8M | $-44.1M | $-64.8M |
| EBITDA | $-68.8M | $-68.8M | $-43.0M | $-33.8M | $-62.6M |
| EPS | -1.81 | -1.81 | -8.60 | -8.31 | -2.12 |
| Gross Margin | 55.4% | 55.4% | 55.1% | 52.6% | 100.0% |
| Operating Margin | -71.5% | -71.5% | -69.5% | -298.9% | -36784.4% |
| Net Margin | -73.0% | -73.0% | -84.1% | -367.6% | -36173.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | -0.03 | -0.02 | -0.02 |
| Current Ratio | 10.69 | 10.69 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-56.2M | $-56.2M | $-51.7M | $-32.8M | $-61.0M |
| Returns | |||||
| ROE | -25.5% | -25.5% | -22.3% | -21.7% | 38.1% |
| Valuation | |||||
| P/B | 1.36 | 1.36 | — | — | — |
| Growth & Yield | |||||
| Revenue Growth | 53.9% | 53.9% | 442.9% | 6601.1% | — |
| EPS Growth | 79.0% | 79.0% | -3.5% | -291.4% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-25.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-8.60 → -1.81
Residual
-25.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.